Health
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch – AlphaStreet
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials of its COVID-19 vaccine a day ago. The stock has gained 9% in the past three months and over 8% in the past one year. The companys vaccine candidate has an advantage over its competitors in terms of dosage and storage but this is being hindered by manufacturing issues.
Trial results
On Wednesday, the results from J&Js interim Phase 1/2a trial were published in…
-
Noosa News15 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
Noosa News23 hours agoTributes flow for Geham wife and mother after husband charged with murder
-
General19 hours agoGerman palliative care doctor with alleged ‘lust for murder’ accused of killing 15 patients
-
Noosa News15 hours agoHow to find out your TikTok personality – and become a ‘citizen scientist’